

Wan-Long Chuang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3533353/publications.pdf>

Version: 2024-02-01

124
papers

6,178
citations

147566
31
h-index

71532
76
g-index

124
all docs

124
docs citations

124
times ranked

6453
citing authors

#	ARTICLE	IF	CITATIONS
1	Predicting portal thrombosis in cirrhosis: Some issues. <i>Journal of Hepatology</i> , 2022, 76, 224-225.	1.8	2
2	Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1273-1282.	0.8	6
3	Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high NANOG expression. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, 38, 157-164.	0.8	1
4	Serum <i>Wisteria floribunda</i> agglutinin-positive Mac-2 binding protein expression predicts disease severity in nonalcoholic steatohepatitis patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, 38, 261-267.	0.8	2
5	Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication. <i>World Journal of Gastroenterology</i> , 2022, 28, 140-153.	1.4	6
6	Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison. <i>World Journal of Gastroenterology</i> , 2022, 28, 263-274.	1.4	10
7	Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1567-1578.	0.8	2
8	Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals. <i>Viruses</i> , 2022, 14, 333.	1.5	2
9	Itemization difference of patient-reported outcome in patients with chronic liver disease. <i>PLoS ONE</i> , 2022, 17, e0264348.	1.1	2
10	Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients. <i>Cancers</i> , 2022, 14, 2023.	1.7	3
11	The compound annual growth rate of the fibrosis index in chronic hepatitis B patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, , .	0.8	0
12	Low disease awareness as a contributing factor to the high prevalence of hepatitis C infection in Tzukuan, a hyperendemic area of southern Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, , .	0.8	2
13	Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients. <i>PLoS ONE</i> , 2022, 17, e0268180.	1.1	2
14	Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 145-153.	0.8	8
15	Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 427-435.	1.4	6
16	Exosome-derived differentiation antagonizing non-protein coding RNA with risk of hepatitis C virus-related hepatocellular carcinoma recurrence. <i>Liver International</i> , 2021, 41, 956-968.	1.9	17
17	The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan. <i>PLoS ONE</i> , 2021, 16, e0246376.	1.1	1
18	Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals. <i>PLoS ONE</i> , 2021, 16, e0245479.	1.1	5

#	ARTICLE	IF	CITATIONS
19	Potential of novel colchicine dosage schedule for the palliative treatment of advanced hepatocellular carcinoma. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 616-623.	0.8	8
20	Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. <i>Liver International</i> , 2021, 41, 1265-1277.	1.9	29
21	Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2247-2254.	1.4	3
22	Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan. <i>BMJ Open</i> , 2021, 11, e042861.	0.8	10
23	Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognostic factor in hepatitis C virus-related hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 313-328.	4.5	8
24	Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. <i>Scientific Reports</i> , 2021, 11, 8184.	1.6	17
25	Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2021, 224, 1890-1899.	1.9	40
26	Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2884-2892.	1.4	10
27	The association between hepatitis C virus infection and renal function. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 757-765.	0.6	5
28	Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed after HCV SVR. <i>Cancers</i> , 2021, 13, 3455.	1.7	11
29	Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection. <i>PLoS ONE</i> , 2021, 16, e0254028.	1.1	6
30	Seroreversion of hepatitis B surface antigen among subjects with resolved hepatitis B virus infection: A community-based cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3239-3246.	1.4	0
31	First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients. <i>Hepatology International</i> , 2021, 15, 1136-1147.	1.9	23
32	IDDF2021-ABS-0079...Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: final 2-year efficacy and safety results from a phase 2. , 2021, , .		0
33	IDDF2021-ABS-0078...Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD). , 2021, , .		0
34	The Prevalence and Serological Association of Hepatitis D Virus Genotypes in Taiwan. <i>Pathogens</i> , 2021, 10, 1227.	1.2	0
35	Scaling up the in-hospital hepatitis C virus care cascade in Taiwan. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 136-143.	4.5	32
36	Path from the discovery to the elimination of hepatitis C virus: Honoring the winners of the Nobel Prize in Physiology or Medicine 2020. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 7-11.	0.8	14

#	ARTICLE	IF	CITATIONS
37	The Persistence of Hepatitis C Virus Infection in Hepatocytes Promotes Hepatocellular Carcinoma Progression by Pro-Inflammatory Interleukin-8 Expression. <i>Biomedicines</i> , 2021, 9, 1446.	1.4	3
38	Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2120-2129.	1.1	13
39	Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication. <i>Clinical Infectious Diseases</i> , 2020, 71, 2840-2848.	2.9	30
40	Clusters of Circulating let-7 Family Tumor Suppressors Are Associated with Clinical Characteristics of Chronic Hepatitis C. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4945.	1.8	9
41	Cure or curd: Modification of lipid profiles and cardiovascular events after hepatitis C virus eradication. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 920-928.	0.8	20
42	Editorial: PNPLA3 genotype and liver diseases—more than nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 390-391.	1.9	1
43	Viral Interference Between Dengue Virus and Hepatitis C Virus Infections. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa272.	0.4	4
44	2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1019-1040.	0.8	60
45	Modelling NAFLD disease burden in four Asian regions—2019–2030. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 801-811.	1.9	92
46	Primary culture of aspiration residual specimens improves the diagnostic accuracy between hepatocellular carcinoma and benign nodules. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 460-466.	0.8	3
47	Editorial: increasing burden of nonalcoholic fatty liver disease—a call to action. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1430-1432.	1.9	0
48	Twelve weeks of ledipasvir/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials. <i>Hepatology Research</i> , 2020, 50, 1109-1117.	1.8	6
49	Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. <i>Journal of Hepatology</i> , 2020, 73, 62-71.	1.8	60
50	Letter to the Editor: Regional Epidemics of Nonalcoholic Fatty Liver Disease: Timing of Westernization and Ethnicity Matter. <i>Hepatology</i> , 2020, 72, 781-781.	3.6	2
51	Primary cultures of aspiration residual specimens predict outcomes of hepatocellular carcinoma patients receiving curative treatment. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 750-756.	0.8	2
52	2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1135-1157.	0.8	69
53	Serial serologic changes of hepatitis D virus in chronic hepatitis B patients receiving nucleos(t)ides analogues therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1886-1892.	1.4	8
54	Circulating exosome DANCR correlated to the recurrence of hepatitis C virus-related hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, e13688-e13688.	0.8	1

#	ARTICLE	IF	CITATIONS
55	Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients. PLoS ONE, 2019, 14, e0220663.	1.1	15
56	The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment. Kaohsiung Journal of Medical Sciences, 2019, 35, 624-632.	0.8	8
57	Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 779-785.	1.5	21
58	Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. Hepatology International, 2019, 13, 587-598.	1.9	27
59	Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study. BMJ Open, 2019, 9, e026703.	0.8	17
60	Integrated care for methadone maintenance patients with hepatitis C virus infection. Kaohsiung Journal of Medical Sciences, 2019, 35, 501-507.	0.8	5
61	IDDF2019-ABS-0168 Bone and renal safety are improved in chronic hbv patients 1 year after switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF). , 2019, , .		0
62	IDDF2019-ABS-0169 A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): week 48 efficacy and safety results. , 2019, , .		0
63	Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. Journal of the Formosan Medical Association, 2019, 118, 556-564.	0.8	11
64	96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. Journal of Hepatology, 2018, 68, 672-681.	1.8	291
65	Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. Gastroenterology, 2018, 154, 989-997.	0.6	97
66	Interference of hepatitis B virus dual infection in platelet count recovery in chronic hepatitis C patients with curative antiviral therapy. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1108-1114.	1.4	6
67	IDDF2018-ABS-0106 Tenofovir alafenamide (taf) compared with tenofovir disoproxil fumarate (tdf) in patients with chronic hbv: week 96 efficacy and safety results in chinese patients enrolled in 2 global phase 3 studies. , 2018, , .		0
68	Updates in the management and treatment of HCV genotype 3, what are the remaining challenges?. Expert Review of Anti-Infective Therapy, 2018, 16, 907-912.	2.0	11
69	Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection. PLoS ONE, 2018, 13, e0202650.	1.1	15
70	Association between cryoglobulinemia and liver fibrosis in chronic hepatitis C patients. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1897-1903.	1.4	6
71	The IL-6/STAT3 pathway upregulates microRNA-125b expression in hepatitis C virus infection. Oncotarget, 2018, 9, 11291-11302.	0.8	19
72	Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C. Oncotarget, 2018, 9, 12240-12249.	0.8	5

#	ARTICLE	IF	CITATIONS
73	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	3.7	1,619
74	25-Hydroxy vitamin D suppresses hepatitis C virus replication and contributes to rapid virological response of treatment efficacy. <i>Hepatology Research</i> , 2017, 47, 1383-1389.	1.8	16
75	Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1754-1762.	1.4	59
76	Heparin at physiological concentration can enhance PEG-free in vitro infection with human hepatitis B virus. <i>Scientific Reports</i> , 2017, 7, 14461.	1.6	16
77	Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment. <i>Clinical Cancer Research</i> , 2017, 23, 1690-1697.	3.2	32
78	Disease severity and erythropoiesis in chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 864-869.	1.4	4
79	Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients. <i>PLoS ONE</i> , 2017, 12, e0174394.	1.1	11
80	Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients. <i>PLoS ONE</i> , 2017, 12, e0178883.	1.1	18
81	The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0184878.	1.1	5
82	Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance. <i>Oncotarget</i> , 2017, 8, 43925-43933.	0.8	12
83	Differences in hepatitis viral etiology of hepatocellular carcinoma in Taiwan and China. <i>Hepatology</i> , 2016, 64, 1008-1009.	3.6	4
84	Long-term efficacy of Peg-Interferon/Ribavirin with and without Lamivudine therapy for HBeAg-positive hepatitis B and C dual infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 835-841.	1.4	8
85	Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. <i>Scientific Reports</i> , 2016, 6, 22995.	1.6	7
86	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. <i>Cancer Cell</i> , 2016, 30, 879-890.	7.7	172
87	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 185-195.	3.7	336
88	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 196-206.	3.7	377
89	The performance of acoustic radiation force impulse imaging in predicting liver fibrosis in chronic liver diseases. <i>Kaohsiung Journal of Medical Sciences</i> , 2016, 32, 362-366.	0.8	22
90	No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw507.	2.9	58

#	ARTICLE	IF	CITATIONS
91	Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter study. <i>Kaohsiung Journal of Medical Sciences</i> , 2016, 32, 559-566.	0.8	2
92	MicroRNA let-7g cooperates with interferon/ribavirin to repress hepatitis C virus replication. <i>Journal of Molecular Medicine</i> , 2016, 94, 311-320.	1.7	12
93	Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy. <i>Oncotarget</i> , 2016, 7, 61325-61335.	0.8	7
94	The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1768-1774.	1.4	14
95	Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C. <i>Medicine (United States)</i> , 2015, 94, e690.	0.4	94
96	PNPLA3 genetic variants determine hepatic steatosis in non-obese chronic hepatitis C patients. <i>Scientific Reports</i> , 2015, 5, 11901.	1.6	9
97	New treatments for HCV: Perspective from Asia. <i>Clinical Liver Disease</i> , 2015, 5, 17-21.	1.0	21
98	Hepatitis C Virus Infection among Injection Drug Users with and without Human Immunodeficiency Virus Co-Infection. <i>PLoS ONE</i> , 2014, 9, e94791.	1.1	44
99	Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. <i>Journal of Hepatology</i> , 2014, 61, 67-74.	1.8	110
100	Hepatitis C viremia interferes with serum hepatitis B virus surface antigen and DNA levels in hepatitis B uremics. <i>Hepatology International</i> , 2014, 8, 224-232.	1.9	12
101	Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection. <i>Antiviral Research</i> , 2014, 105, 135-142.	1.9	16
102	High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients. <i>Journal of Hepatology</i> , 2014, 60, 253-259.	1.8	58
103	The safety and efficacy of peginterferon plus ribavirin in hepatitis C patients concomitant with malignancy other than hepatocellular carcinoma: a multicenter study. <i>Hepatology International</i> , 2013, 7, 180-187.	1.9	2
104	The Evolution of HCV Treatment in Taiwan. <i>Current Hepatitis Reports</i> , 2013, 12, 143-148.	0.3	0
105	Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. <i>Hepatology</i> , 2013, 57, 2135-2142.	3.6	66
106	Host factors determining the efficacy of hepatitis C treatment. <i>Journal of Gastroenterology</i> , 2013, 48, 22-30.	2.3	28
107	Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. <i>Journal of Hepatology</i> , 2012, 56, 34-40.	1.8	77
108	Thyroid autoantibodies and dysfunction do not impact the treatment efficacy of peginterferon and ribavirin combination therapy in chronic hepatitis C. <i>Hepatology International</i> , 2012, 6, 613-619.	1.9	4

#	ARTICLE	IF	CITATIONS
109	APASL consensus statements and management algorithms for hepatitis C virus infection. <i>Hepatology International</i> , 2012, 6, 409-435.	1.9	152
110	Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1. <i>Antiviral Research</i> , 2012, 93, 239-244.	1.9	44
111	Performance characteristics of a combined hepatitis C virus core antigen and anti-hepatitis C virus antibody test in different patient groups. <i>Kaohsiung Journal of Medical Sciences</i> , 2011, 27, 258-263.	0.8	16
112	The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. <i>Liver International</i> , 2011, 31, 1326-1331.	1.9	65
113	Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. <i>Hepatology</i> , 2011, 53, 7-13.	3.6	168
114	Insurance status and treatment candidacy of patients with hepatitis C: Taiwanese patients are luckier. <i>Hepatology</i> , 2011, 53, 1399-1399.	3.6	7
115	Hepatitis C virus viremia and low platelet count: A study in a hepatitis B & C endemic area in Taiwan. <i>Journal of Hepatology</i> , 2010, 52, 160-166.	1.8	47
116	Viral Hepatitis Infections in Southern Taiwan: A Multicenter Community-based Study. <i>Kaohsiung Journal of Medical Sciences</i> , 2010, 26, 461-469.	0.8	100
117	Treatment of chronic hepatitis C in Asia: When East meets West. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 336-345.	1.4	227
118	Performance characteristics of two real-time PCR assays for quantification of hepatitis B virus DNA. <i>Scandinavian Journal of Infectious Diseases</i> , 2009, 41, 614-618.	1.5	15
119	Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial. <i>Hepatology</i> , 2008, 47, 1884-1893.	3.6	299
120	A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. <i>Gut</i> , 2007, 56, 553-559.	6.1	257
121	A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. <i>Hepatology</i> , 2006, 44, 1086-1097.	3.6	107
122	Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan. <i>Liver International</i> , 2004, 24, 595-602.	1.9	14
123	Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 636-640.	1.4	56
124	Role of serum C-reactive protein as a marker of hepatocellular carcinoma in patients with cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 417-421.	1.4	22